重组人血管内皮抑制素联合顺铂治疗恶性胸腹水疗效观察

Effect of recombinant human endostatin combined with cis-Diammineplatinum on malignant pleural effusion and ascites

目的探讨重组人血管内皮抑制素联合顺铂治疗恶性胸腹水的疗效。方法选取2013年10月至2015年10月期间在河北省唐山市人民医院就诊的恶性胸腹水86例患者,采用随机数表法分为观察组与对照组,每组43例。观察组患者采用重组人血管内皮抑制素联合顺铂治疗,对照组患者则采用顺铂治疗,两周为一个疗程。治疗一个疗程后,比较两组的治疗效果、血常规各项指标以及生活质量的差异。结果观察组患者的治疗有效率为76.7%,明显高于对照组30.2%,差异具有统计学意义(P<0.05);治疗后,观察组患者的淋巴细胞[(1.44±0.42)×10-9/L vs(1.20±0.60)×10-9/L]、白细胞[(4.55±2.08)×10-9/L vs(3.81±1.19)×10-9/L]、血小板[(187.64±63.71)×10-9/L vs(150.42±89.82)×10-9/L]、血红蛋白[(108.55±17.66)g/L vs(99.77±17.65)g/L]水平均高于对照组,差异均具有统计学意义(P<0.05);在生活质量方面,观察组患者各维度评分均高于对照组,差异均具有统计学意义(P<0.05)。结论采用重组人血管内皮抑制素联合顺铂治疗恶性胸腹水,不仅可有效提高治疗效果,且对患者血细胞水平影响较低,同时可以提高患者生活质量,值得临床推广使用。

Objective To observe the effects of recombinant human endostatin combined with cis-Diammineplatinum on malignant pleural effusion and ascites. Methods A total of 86 cases of patients with malignant pleural effusion and ascites, who admitted to Tangshan People's Hospital from October 2013 to October 2015, were selected and randomly divided into the treatment group(received endostatin combined with cis-Diammineplatinum therapy) and the control group(received cis-Diammineplatinum therapy), with 43 cases in each group. Two weeks were taken as a course.The therapy effects, blood routine examination and life quality of the two groups were compared after a course of treatment. Results The therapy effects of the treatment group(76.7%) were significantly better than those of control group(30.2%), P<0.05. The lymphocytes, white blood cells, platelet, hemoglobin of the treatment group were significantly higher than those of the control group, with(1.44±0.42)×10-9/L vs(1.20±0.60)×10-9/L,(4.55±2.08)×10-9/L vs(3.81±1.19)×10-9/L,(187.64±63.71)×10-9/L vs(150.42±89.82)×10-9/L,(108.55±17.66) g/L vs(99.77±17.65) g/L, respectively, P<0.05.The life quality in treatment group were significantly better than that in the control group(P<0.05). Conclusion Endostatin combined with cis-Diammineplatinum can not only has a good therapy effect on the patients with malignant pleural effusion and ascites, but also can improve the quality of life of patients, with lower effect on patients' blood routine examination simultaneously. It is worthy of clinical promotion.